EUVIMEDEUVIMED entdecken
Kohortenstudie

Mortality and Survival Analysis in Patients With Cancer Occurrence After Sjögren's Syndrome: A Long‐Term Cohort Study in China

Yezi Peng iD, Jiana Chen, Yafei Ren, Dan Yang, Ziyue Zhou, Xiangyi Shen iD, Junyan Qian, Xu Jiang, Lidan Zhao, Yunyun Fei, Hua Chen, Mengtao Li und 2 weitere

International Journal of Rheumatic Diseases · 2025

DOI: 10.1111/1756-185x.70059 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Yezi Peng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Educatio…. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Neoplasms. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Chinese Academy of Medical Science Innovation Fund for Medical Sciences, Peking Union Medical College Hospital Research funding for Postdoc, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to investigate the mortality, survival rates, and prognostic indicators of cancer occurrence after Sjögren's syndrome (SS‐CA).

Methods

The medical records of patients with SS‐CA at the Peking Union Medical College Hospital (PUMCH) between January 2010 and August 2022 were retrieved. Clinical data and survival outcomes were compared to controls. The standard mortality ratio (SMR) versus the general population was calculated, and the survival and predictive markers of prognosis were analyzed using Kaplan–Meier curves and Cox regression.

Results

In total, 114 SS‐CA patients were included, with a median follow‐up time of 105.1 (57.3–168.0) months. Non‐Hodgkin lymphoma (32, 28.1%) was the most common cancer in patients with SS‐CA. The SMR of SS‐CA patients was 2.61 (95% confidence interval [CI] 1.73–3.77). Patients with SS‐CA exhibited significantly inferior outcomes compared to controls ( p = 0.010), with 5‐ and 10‐year overall survival rates of 91.2% and 83.2%, respectively. SS patients with a diagnostic interval between SS and cancer (SS‐CA diagnostic interval) ≤ 3 years or with hematological malignancies had poorer survival compared to those with a diagnostic interval > 3 years ( p < 0.001) or with solid tumors ( p = 0.019). Multivariate Cox regression analysis identified the prognosis‐associated factors of SS‐CA as age at SS diagnosis > 50 years (HR 3.129, 95% CI 1.224–7.998; p = 0.017), SS‐CA diagnostic interval ≤ 3 years (HR 7.754, 95% CI 1.953–30.781; p = 0.004), and hematological malignancies (HR 2.648, 95% CI 1.201–5.838; p = 0.016).

Conclusion

Malignant comorbidities constituted a poor prognosis in patients with SS, wherein the SS‐CA diagnostic interval and the types of cancer were associated with survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeNeoplasmsHumansFemaleMiddle AgedMaleTime FactorsRisk FactorsChinaAdultAgedRetrospective StudiesKaplan-Meier EstimateProportional Hazards ModelsPrognosis

Stichwörter der Autor:innen

Sjögren's syndromecancermortalitysurvival analysis

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Acade…
  • State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Rheumatology and Immunology, Affiliated Hospital of Guilin Medical University, Guilin, China.
  • School of Medicine, Tsinghua University, Beijing, China.
  • National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Yezi Peng, Xiangyi Shen, Huaxia Yang

Förderung

  • Chinese Academy of Medical Science Innovation Fund for Medical Sciences
  • Peking Union Medical College Hospital Research funding for Postdoc
  • National Natural Science Foundation of China
  • National High-Level Hospital Clinical Research Funding

Zitieren

APA

Peng, Y., Chen, J., Ren, Y., Yang, D., Zhou, Z., Shen, X., Qian, J., Jiang, X., Zhao, L., Fei, Y., Chen, H., Li, M., Yang, H., & Zhang, F. (2025). Mortality and Survival Analysis in Patients With Cancer Occurrence After Sjögren's Syndrome: A Long‐Term Cohort Study in China. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70059

Vancouver

Peng Y, Chen J, Ren Y, Yang D, Zhou Z, Shen X, et al. Mortality and Survival Analysis in Patients With Cancer Occurrence After Sjögren's Syndrome: A Long‐Term Cohort Study in China. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70059

BibTeX
@article{Peng2025,
  author = {Peng, Yezi and Chen, Jiana and Ren, Yafei and Yang, Dan and Zhou, Ziyue and Shen, Xiangyi and Qian, Junyan and Jiang, Xu and Zhao, Lidan and Fei, Yunyun and Chen, Hua and Li, Mengtao and Yang, Huaxia and Zhang, Fengchun},
  title = {Mortality and Survival Analysis in Patients With Cancer Occurrence After Sjögren's Syndrome: A Long‐Term Cohort Study in China},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  doi = {10.1111/1756-185x.70059}
}
Kostenlos starten →